Alzheimer's drugs take a new tack
E Callaway - Nature, 2012 - go.gale.com
E Callaway
Nature, 2012•go.gale.comAfter a summer marred by disappointing clinical-trial results in patients with Alzheimer's
disease, drug developers are regrouping to plot a fresh course in the battle against the
devastating disorder.The bad news began in July and August, when Johnson & Johnson
and Pfizer learned that their biological drug bapineuzumab had failed to show any benefit in
two large trials. Then, on 24 August, Eli Lilly said that its drug solanezumab had not hit its
goal of significantly slowing the memory decline and dementia that characterize Alzheimer's …
disease, drug developers are regrouping to plot a fresh course in the battle against the
devastating disorder.The bad news began in July and August, when Johnson & Johnson
and Pfizer learned that their biological drug bapineuzumab had failed to show any benefit in
two large trials. Then, on 24 August, Eli Lilly said that its drug solanezumab had not hit its
goal of significantly slowing the memory decline and dementia that characterize Alzheimer's …
After a summer marred by disappointing clinical-trial results in patients with Alzheimer's disease, drug developers are regrouping to plot a fresh course in the battle against the devastating disorder.
The bad news began in July and August, when Johnson & Johnson and Pfizer learned that their biological drug bapineuzumab had failed to show any benefit in two large trials. Then, on 24 August, Eli Lilly said that its drug solanezumab had not hit its goal of significantly slowing the memory decline and dementia that characterize Alzheimer's disease.
Gale